Using point of care testing and over the counter therapies to lessen the burden of allergic diseases
The prevalence of allergic diseases is increasing worldwide, and every year 400 million people suffer from allergic rhinitis. Allergic diseases are becoming an increasing public health concern and an economic burden. The costs for treating rhinitis in the US have doubled in 5 years to 11 billion US$.
In 2010, the World Health Organisation (WHO) recommended that all suspected cases of malaria be confirmed with a diagnostic test prior to treatment. Since this mandate rapid diagnostic tests (RDTs) have become the first-choice diagnostic tool for malaria despite test accuracy varying between brands, location and epidemiology settings.
The over the counter (OTC) marketplace is a particularly busy and congested retail space, with many big brands competing for position in a highly-regulated environment. Brand owners need to constantly explore new ways of attracting customers to retain and expand their market share and add value to their brand through innovation.
This article explores the mechanisms of antigen processing and how this contributes to T cell recognition of antigen and the regulation of the immune response.
Although lateral flow tests are simple and straightforward technology, there are multiple important steps to get right when developing a robust, reliable lateral flow test that will deliver the best results.
The economic costs of infectious diseases – especially HIV/AIDS and malaria – are significant. One of the key challenges within this market place is the accurate diagnosis of a disease to support early prevention and treatment. Discover BBI Solutions' capabilities including the production of over 600,000 tests for our customers in the infectious disease area last year.
In January of 2017, the Food and Drug Administration agency (FDA) re-classified rapid antigen based diagnostic devices used to test for influenza. Manufacturers of flu rapid test need to increase the sensitivity of their assays to meet these new requirements.
Dr Neil Polwart, NovarumTM DX founder and BBI Group Head of Mobile, has over a decade of experience in the delivery of next generation diagnostic technologies within mobile health (mHealth).
In the UK, the National Health Service (NHS) is suffering to cope with the pressure of rising patient demand, staff shortages and political pressures. With the drive towards self-care as a potential answer to some of the pressures on the NHS, the use of technology to support self-care will be key.